Mouse models of cancer

Annual Review of Pathology: Mechanisms of Disease

Volumn 6, Issue , 2011, Pages 95-119

  Cheon, Dong Joo ^a   Orsulic, Sandra ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

cancer gene discovery; gene targeting; genetically engineered mice; oncogene; oncogenomics; tumor suppressor gene

Indexed keywords

BIOLOGICAL MARKER; ETHYLNITROSOUREA; GENE PRODUCT; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER RESEARCH; CHROMOSOME DELETION; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION; ENVIRONMENTAL FACTOR; GENE LOCUS; GENE MUTATION; GENE TARGETING; GENETIC ENGINEERING; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; MOUSE; MUTAGENESIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SPECIES DIFFERENCE; TRANSPOSON; TUMOR GENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS;

EID: 79751514764     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.3.121806.154244     Document Type: Article

References (143)

1. Stewart TA, Pattengale PK, Leder P. 1984. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MT (Pubitemid 15176093)
2. Brinster RL, ChenHY, Messing A, vanDyke T, Levine AJ, et al. 1984. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 37:367-79 (Pubitemid 14079032)
3. Hanahan D. 1985. Heritable formation of pancreatic â-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315:115-22 (Pubitemid 15064530)
4. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, et al. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenicmice. Nature 318:533-38 (Pubitemid 16173038)
5. Thomas KR,CapecchiMR. 1987. Site-directedmutagenesis by gene targeting inmouse embryo-derived stem cells. Cell 51:503-12
6. Frese KK, Tuveson DA. 2007. Maximizing mouse cancer models. Nat. Rev. Cancer 7:645-58 (Pubitemid 47327410)
7. Grisendi S, Pandolfi PP. 2004. Germline modification strategies. In Mouse Models of Human Cancer, ed. EC Holland, pp. 43-63. New York: Wiley
8. Nagy A, Gertsenstein M, Vintersten K, Behringer R. 2003. Manipulating theMouse Embryo. Cold Spring Harbor, NY: Cold Spring Harbor Lab. 3rd ed.
9. Rose-Hellekant TA, Sandgren EP. 2000. Transforming growth factor á- and c-myc-induced mammary carcinogenesis in transgenic mice. Oncogene 19:1092-96 (Pubitemid 30153795)
10. Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, et al. 2009. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev. Mol. Diagn. 9:423-40
11. Breuer M, Wientjens E, Verbeek S, Slebos R, Berns A. 1991. Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras. Cancer Res. 51:958-63
12. van LohuizenM, Verbeek S, Krimpenfort P,Domen J, Saris C, et al. 1989. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56:673-82 (Pubitemid 19065532)
13. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. 2002. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295:868-72 (Pubitemid 34118370)
14. Novak A, Guo C, Yang W, Nagy A, Lobe CG. 2000. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 28:147-55
15. West AG, Gaszner M, Felsenfeld G. 2002. Insulators: many functions, many mechanisms. Genes Dev. 16:271-88 (Pubitemid 34111407)
16. Beard C, Hochedlinger K, Plath K,Wutz A, Jaenisch R. 2006. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44:23-28 (Pubitemid 43222207)
17. An W, Han JS, Schrum CM, Maitra A, Koentgen F, et al. 2008. Conditional activation of a single-copy L1 transgene in mice by Cre. Genesis 46:373-83
18. Wallace HA, Marques-Kranc F, Richardson M, Luna-Crespo F, Sharpe JA, et al. 2007. Manipulating the mouse genome to engineer precise functional syntenic replacements with human sequence. Cell 128:197-209 (Pubitemid 46048892)
19. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, et al. 1992. Effects of an Rb mutation in the mouse. Nature 359:295-300
20. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, et al. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-21
21. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, et al. 1996. The tumor-suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85:1009-23 (Pubitemid 26231168)
22. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. 1996. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12:191-94 (Pubitemid 26051301)
23. Friedrich G, Soriano P. 1991. Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev. 5:1513-23 (Pubitemid 21906058)
24. de Vries A, Flores ER, Miranda B,Hsieh HM, van OostromCT, et al. 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc.Natl. Acad. Sci. USA 99:2948-53 (Pubitemid 34240566)
25. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111-16 (Pubitemid 32391044)
26. Hoess RH, Wierzbicki A, Abremski K. 1986. The role of the loxP spacer region in P1 site-specific recombination. Nucleic Acids Res. 14:2287-300
27. Xu X, Wagner KU, Larson D,Weaver Z, Li C, et al. 1999. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat. Genet. 22:37-43 (Pubitemid 29214802)
28. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, et al. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:3243-48 (Pubitemid 34008190)
29. Soriano P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21:70-71 (Pubitemid 29036285)
30. Pfeifer A, Brandon EP, Kootstra N, Gage FH, Verma IM. 2001. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc. Natl. Acad. Sci. USA 98:11450-55 (Pubitemid 32928749)
31. Jo D, Nashabi A, Doxsee C, Lin Q, Unutmaz D, et al. 2001. Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase. Nat. Biotechnol. 19:929-33 (Pubitemid 32947570)
32. Fisher EM, Lana-Elola E, Watson SD, Vassiliou G, Tybulewicz VL. 2009. New approaches for modelling sporadic genetic disease in the mouse. Dis. Model Mech. 2:446-53
33. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. 1999. Reversible activation of c-myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3:565-77 (Pubitemid 29268440)
34. MehassebMK, Bell SC, HabibaMA. 2009. The effects of tamoxifen and estradiol on myometrial differentiationand organization during early uterine development in the CD1mouse. Reproduction 138:341-50
35. Higashi AY, IkawaT,Muramatsu M, Economides AN,Niwa A, et al. 2009. Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2. J. Immunol. 182:5633-40
36. Chin L, Tam A, Pomerantz J, Wong M, Holash J, et al. 1999. Essential role for oncogenic Ras in tumor maintenance. Nature 400:468-72 (Pubitemid 29361802)
37. Fisher GH,Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, et al. 2001. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor-suppressor genes. Genes Dev. 15:3249-62 (Pubitemid 34008191)
38. Yu Y, Bradley A. 2001. Engineering chromosomal rearrangements in mice. Nat. Rev. Genet. 2:780-90 (Pubitemid 33685575)
39. Buchholz F, Refaeli Y, Trumpp A, Bishop JM. 2000. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep. 1:133-39
40. Bagchi A, Papazoglu C,Wu Y, Capurso D, Brodt M, et al. 2007. CHD5 is a tumor suppressor at human 1p36. Cell 128:459-75 (Pubitemid 46198889)
41. Coumoul X, Shukla V, Li C,Wang RH, Deng CX. 2005. Conditional knockdown of Fgfr2 in mice using Cre-LoxP induced RNA interference. Nucleic Acids Res. 33:e102
42. Dickins RA, McJunkin K, Hernando E, Premsrirut PK, Krizhanovsky V, et al. 2007. Tissue-specific and reversible RNA interference in transgenic mice. Nat. Genet. 39:914-21 (Pubitemid 47014488)
43. Kunath T, Gish G, Lickert H, Jones N, Pawson T, et al. 2003. Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nat. Biotechnol. 21:559-61 (Pubitemid 36532022)
44. Rao MK, Pham J, Imam JS, MacLean JA, Murali D, et al. 2006. Tissue-specific RNAi reveals that WT1 expression in nurse cells controls germ cell survival and spermatogenesis. Genes Dev. 20:147-52 (Pubitemid 43112933)
45. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, et al. 2004. Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl. Acad. Sci. USA 101:10380-85 (Pubitemid 38924934)
46. Uhrbom L, Holland EC. 2004. Somatic cell gene transfer. In Mouse Models of Human Cancer, ed. EC Holland, pp. 67-79. New York: Wiley
47. Wang Y, Krushel LA, Edelman GM. 1996. Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene. Proc. Natl. Acad. Sci. USA 93:3932-36 (Pubitemid 26144225)
48. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, et al. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11:63-70 (Pubitemid 40215839)
49. Zender L, SpectorMS, XueW, Flemming P, Cordon-Cardo C, et al. 2006. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125:1253-67 (Pubitemid 43929093)
50. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, et al. 2002. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62 (Pubitemid 41039176)
51. Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, et al. 2004. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23:6156-62 (Pubitemid 39178868)
52. Zhou Y, Rideout WM 3rd, Zi T, Bressel A, Reddypalli S, et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat. Biotechnol. 28:71-78
53. Zong H, Espinosa JS, Su HH, MuzumdarMD, Luo L. 2005. Mosaic analysis with doublemarkers in mice. Cell 121:479-92
54. Luo L. 2007. Fly MARCM and mouse MADM: genetic methods of labeling and manipulating single neurons. Brain Res. Rev. 55:220-27 (Pubitemid 47538750)
55. Muzumdar MD, Luo L, ZongH. 2007. Modeling sporadic loss of heterozygosity inmice by usingmosaic analysis with double markers (MADM). Proc. Natl. Acad. Sci. USA 104:4495-500 (Pubitemid 47186253)
56. Espinosa JS,Wheeler DG, Tsien RW, Luo L. 2009. Uncoupling dendrite growth and patterning: singlecell knockout analysis of NMDA receptor 2B. Neuron 62:205-17
57. Wang W, Warren M, Bradley A. 2007. Induced mitotic recombination of p53 in vivo. Proc. Natl. Acad. Sci. USA 104:4501-5 (Pubitemid 47186254)
58. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, et al. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7
59. Mattison J, van derWeyden L, Hubbard T, Adams DJ. 2009. Cancer gene discovery in mouse and man. Biochim. Biophys. Acta 1796:140-61
60. Uren AG, Kool J, Berns A, van LohuizenM. 2005. Retroviral insertional mutagenesis: past, present and future. Oncogene 24:7656-72 (Pubitemid 41670669)
61. Selten G, Cuypers HT, Zijlstra M, Melief C, Berns A. 1984. Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J. 3:3215-22
62. Mucenski ML, Taylor BA, Ihle JN, Hartley JW,Morse HC 3rd, et al. 1988. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol. Cell Biol. 8:301-8 (Pubitemid 18015584)
63. Selten G, Cuypers HT, Berns A. 1985. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J. 4:1793-98
64. Suzuki T, Minehata K, AkagiK, Jenkins NA,CopelandNG. 2006. Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient mice. EMBO J. 25:3422-31 (Pubitemid 44141798)
65. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, et al. 1991. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65:737-52 (Pubitemid 121001306)
66. Johansson FK, Brodd J, EklofC, Ferletta M, Hesselager G, et al. 2004. Identification of candidate cancercausing genes in mouse brain tumors by retroviral tagging. Proc. Natl. Acad. Sci. USA 101:11334-37
67. Russell WL, Kelly EM, Hunsicker PR, Bangham JW,Maddux SC, et al. 1979. Specific-locus test shows ethylnitrosourea to be the most potent mutagen in the mouse. Proc. Natl. Acad. Sci. USA 76:5818-19 (Pubitemid 10168696)
68. Gondo Y, Fukumura R, Murata T, Makino S. 2009. Next-generation gene targeting in the mouse for functional genomics. BMB Rep. 42:315-23
69. Moser AR, Pitot HC, Dove WF. 1990. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247:322-24
70. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, et al. 1992. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256:668-70
71. Demant P. 1992. Genetic resolution of susceptibility to cancer-new perspectives. Semin. Cancer Biol. 3:159-66
72. Demant P. 2003. Cancer susceptibility in the mouse: genetics, biology and implications for human cancer. Nat. Rev. Genet. 4:721-34 (Pubitemid 37046139)
73. Ruivenkamp CA, van Wezel T, Zanon C, Stassen AP, Vlcek C, et al. 2002. Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat. Genet. 31:295-300
74. Youngren KK, Coveney D, Peng X, Bhattacharya C, Schmidt LS, et al. 2005. The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. Nature 435:360-64 (Pubitemid 40745546)
75. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, et al. 2005. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat. Genet. 37:1055-62 (Pubitemid 41486657)
76. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. 2005. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436:272-76 (Pubitemid 41021279)
77. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. 2005. Mammalian mutagenesis using a highly mobile somatic sleeping beauty transposon system. Nature 436:221-26 (Pubitemid 41021267)
78. Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, et al. 2009. A conditional transposonbased insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 27:264-74
79. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, et al. 2009. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323:1747-50
80. Dupuy AJ, Rogers LM, Kim J, Nannapaneni K, Starr TK, et al. 2009. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res. 69:8150-56
81. Collier LS, Largaespada DA. 2005. Hopping around the tumor genome: transposons for cancer gene discovery. Cancer Res. 65:9607-10 (Pubitemid 41541432)
82. Izsvak Z, Ivics Z, Plasterk RH. 2000. Sleeping beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J. Mol. Biol. 302:93-102
83. Geurts AM, Yang Y, Clark KJ, Liu G, Cui Z, et al. 2003. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol. Ther. 8:108-17 (Pubitemid 36939302)
84. Cadinanos J, Bradley A. 2007. Generation of an inducible and optimized piggyBac transposon system. Nucleic Acids Res. 35:e87
85. Ding S,WuX, Li G, HanM,ZhuangY, et al. 2005. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122:473-83 (Pubitemid 41127147)
86. Wu S, Ying G, Wu Q, Capecchi MR. 2007. Toward simpler and faster genome-wide mutagenesis in mice. Nat. Genet. 39:922-30 (Pubitemid 47014495)
87. MurrayWS. 1928. A note on ovarian secretion and cancer. Science 67:396-97
88. Jordan VC. 1977. Effects of tamoxifen in relation to breast cancer. Br. Med. J. 1:1534-35 (Pubitemid 8115362)
89. Tannenbaum A, SilverstoneH. 1949. The influence of the degree of caloric restriction on the formation of skin tumors and hepatomas in mice. Cancer Res. 9:724-27
90. Wasan HS, Novelli M, Bee J, Bodmer WF. 1997. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc. Natl. Acad. Sci. USA 94:3308-13 (Pubitemid 27157307)
91. Noonan FP, Otsuka T, Bang S, Anver MR, Merlino G. 2000. Accelerated UV radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice. Cancer Res. 60:3738-43 (Pubitemid 32204561)
92. Noonan FP, Recio JA, Takayama H, Duray P, Anver MR, et al. 2001. Neonatal sunburn and melanoma in mice. Nature 413:271-72 (Pubitemid 32905840)
93. Aszterbaum M, Epstein J, Oro A, Douglas V, LeBoit PE, et al. 1999. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat. Med. 5:1285-91 (Pubitemid 29535606)
94. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M. 2001. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of â-catenin-mutated mouse liver tumors. Oncogene 20:7812-16 (Pubitemid 33121956)
95. Lyons SK. 2005. Advances in imaging mouse tumor models in vivo. J. Pathol. 205:194-205 (Pubitemid 40227991)
96. Stell A, Biserni A, Della Torre S, Rando G, Ramachandran B, et al. 2007. Cancer modeling: modern imaging applications in the generation of novel animal model systems to study cancer progression and therapy. Int. J. Biochem. Cell Biol. 39:1288-96 (Pubitemid 47031034)
97. Hoffman RM. 2009. Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clin. Exp. Metastasis 26:345-55
98. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, et al. 1998. Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715-25 (Pubitemid 28436004)
99. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, et al. 2006. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc. Natl. Acad. Sci. USA 103:105-10 (Pubitemid 43076112)
100. Vooijs M, Jonkers J, Lyons S, Berns A. 2002. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res. 62:1862-67 (Pubitemid 34408514)
101. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, et al. 2006. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-81 (Pubitemid 43949521)
102. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, et al. 2005. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37:48-55 (Pubitemid 40070939)
103. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, et al. 2008. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135:852-64
104. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, et al. 2008. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 22:1439-44 (Pubitemid 351793078)
105. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, et al. 2009. Functional identification of tumorsuppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16:324-35
106. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-12 (Pubitemid 29291347)
107. Huss WJ, Barrios RJ, Greenberg NM. 2003. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. Mol. Cancer Ther. 2:611-16
108. Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, et al. 2009. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23:877-89
109. Sharpless NE, Depinho RA. 2006. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5:741-54 (Pubitemid 44323701)
110. Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, et al. 2000. Mouse mammary tumor virus-KirasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res. 60:2680-88 (Pubitemid 30318244)
111. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. 2005. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309 (Pubitemid 41443415)
112. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, et al. 2002. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8:459-65 (Pubitemid 34546747)
113. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP. 2000. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARáand PLZF-RARáoncoproteins. Proc. Natl. Acad. Sci. USA 97:10173-78
114. Lallemand-Breitenbach V, GuilleminMC, Janin A, DanielMT, Degos L, et al. 1999. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189:1043-52 (Pubitemid 29169821)
115. Hanash SM, Pitteri SJ, Faca VM. 2008. Mining the plasma proteome for cancer biomarkers. Nature 452:571-79 (Pubitemid 351483371)
116. Hingorani SR, Petricoin EF,Maitra A, Rajapakse V, King C, et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437-50 (Pubitemid 38050041)
117. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, et al. 2008. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 5:e123
118. Hung KE, Faca V, Song K, Sarracino DA, Richard LG, et al. 2009. Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev. Res. 2:224-33
119. Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, et al. 2007. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 6:3962-75 (Pubitemid 350032560)
120. Pitteri SJ, JeBailey L, Faca VM, Thorpe JD, Silva MA, et al. 2009. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One 4:e7916
121. Katoh Y, Katoh M. 2009. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 9:873-86
122. Polakis P. 2007. The many ways ofWnt in cancer. Curr. Opin. Genet. Dev. 17:45-51
123. Xu X, Qiao W, Linke SP, Cao L, LiWM, et al. 2001. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 28:266-71 (Pubitemid 32626030)
124. Ramus SJ, Bobrow LG, Pharoah PD, Finnigan DS, Fishman A, et al. 1999. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 25:91-96 (Pubitemid 29226590)
125. Knudson AG Jr. 1986. Genetics of human cancer. Annu. Rev. Genet. 20:231-51
126. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. 1998. The murine gene p27Kip1 is haploinsufficient for tumor suppression. Nature 396:177-80 (Pubitemid 28523620)
127. Xing D, Orsulic S. 2006. A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma. Cancer Res. 66:8949-53 (Pubitemid 44521109)
128. Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, et al. 2004. MYC is amplified in BRCA1- associated breast cancers. Clin. Cancer Res. 10:499-507 (Pubitemid 38173988)
129. Meuwissen R, Jonkers J, Berns A. 2001. Mouse models for sporadic cancer. Exp. Cell Res. 264:100-10 (Pubitemid 32989084)
130. de la Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, et al. 1999. Paradoxical inhibition of c-mycinduced carcinogenesis by Bcl-2 in transgenic mice. Cancer Res. 59:5017-22 (Pubitemid 29472909)
131. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, et al. 2008. Distinct thresholds governMyc's biological output in vivo. Cancer Cell 14:447-57
132. Harris AL. 2002. Hypoxia-a key regulatory factor in tumor growth. Nat. Rev. Cancer 2:38-47 (Pubitemid 37328806)
133. Shchors K, Evan G. 2007. Tumor angiogenesis: cause or consequence of cancer? Cancer Res. 67:7059-61 (Pubitemid 47206529)
134. Tennant DA, Duran RV, Boulahbel H, Gottlieb E. 2009. Metabolic transformation in cancer. Carcinogenesis 30:1269-80
135. Hill R, Song Y, Cardiff RD, Van Dyke T. 2005. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123:1001-11 (Pubitemid 41785416)
136. Li X, Placencio V, Iturregui JM,Uwamariya C, Sharif-Afshar AR, et al. 2008. Prostate tumor progression is mediated by a paracrine TGF-â/Wnt3a signaling axis. Oncogene 27:7118-30
137. Yeang CH, McCormick F, Levine A. 2008. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 22:2605-22
138. Peeper D, Berns A. 2006. Cross-species oncogenomics in cancer gene identification. Cell 125:1230-33 (Pubitemid 43929103)
139. Hann B, Balmain A. 2001. Building "validated" mouse models of human cancer. Curr. Opin. Cell Biol. 13:778-84 (Pubitemid 33042740)
140. Rangarajan A, Weinberg RA. 2003. Opinion. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer 3:952-59 (Pubitemid 37500180)
141. Maser RS, Choudhury B, Campbell PJ, Feng B,Wong KK, et al. 2007. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447:966-71 (Pubitemid 46975753)
142. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-38 (Pubitemid 120031831)
143. Frijhoff AF, Conti CJ, Senderowicz AM. 2004. Advances in molecular carcinogenesis: current and future use ofmousemodels to screen and validatemolecularly targeted anticancer drugs. Mol. Carcinog. 39:183-94 (Pubitemid 38452238)